HOXB9 activation is reported to induce chemoresistance to anti-VEGF bevacizumab in colorectal cancer xenograft mouse models via altering angiogenic factors expression such as CXCL1, TGF-β1, angiopoietin-like 2 (Angptl2), and IL8 (Carbone et al. 2017). The gene discussed is ANGPTL2; the disease is colorectal cancer.